Novartis/Spark’s sight gene therapy approved in EUSpark Therapeutics’ gene therapy for a rare inherited sight disorder, Luxturna has been approved in Europe, but there Share XNovartis/Spark’s sight gene therapy approved in EUhttps://pharmaphorum.com/news/novartis-sparks-sight-gene-therapy-approved-in-eu/
